A double blind placebo controlled clinical trial to evaluate the efficacy and safety of Shatavari in Menstrual irregularity

A double blind placebo controlled clinical trial to evaluate the efficacy and safety of Shatavari in Menstrual irregularity - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/06/001804

Enrollment

Registered

2011-06-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Menstrual irregularity

Interventions

Intervention1: Shatavari: Dose - 1 caplet of Shatavari thrice daily Duration of treatment - 3 months Mode of administration - oral Control Intervention1: Placebo: Dose - 1 caplet of Placebothrice dai

Eligibility

Inclusion criteria

Inclusion criteria: Females above the age of 45 with postmenopausal symptoms like hot flashes, night sweats, dry itchy skin, sleep disturbances, irritability, joint pain, anxiety or depression will be included in the study.

Exclusion criteria

Exclusion criteria: Subjects suffering from serious life threatening disorders or participated in a similar study within past 1 month will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Improvement in post menopausal symptoms.Timepoint: 3 months	—

Secondary

Measure	Time frame
Assessment of long term safety of Shatavari caplet.Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Sharda More

drshardamore@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026